1393809-97-6

Upstream product

• 1393809-78-3 2-(allyl((1S,2R)-1-(4-bromophenyl)-1,3-dihydroxypropan-2-yl)amino)acetonitrile 
• 1393809-83-0 2-(allyl((1S,2R)-1-(4-bromophenyl)-1-chloro-3-(trityloxy)propan-2-yl)amino)acetonitrile 
• 115362-13-5 [(2R,3R)-3-(4-bromophenyl)oxiran-2-yl]methanol 
• 1393809-90-9 (2S,3S,4R)-1-allyl-3-(4-bromophenyl)-2-((trityloxy)methyl)azetidine-4-carbonitrile 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 1393809-77-2 C₁₂H₁₆BrNO₂ 

Downstream Products

• 1393810-18-8 C₄₂H₄₀BrN₃O₅S 
• 1393810-30-4 [(8R,9S,10S)-9-(4-bromophenyl)-6-[(2-nitrophenyl)sulfonyl]-1,6-diazabicyclo[6.2.0]decan-10-yl]methanol 
• 1393810-14-4 (6R,7S,8S)-7-(4-bromophenyl)-8-(hydroxymethyl)-4-((2-nitrophenyl)sulfonyl)-1,4-diazabicyclo[4.2.0]octan-2-one 
• 1393810-10-0 (6R,7S,8S)-7-(4-bromophenyl)-4-((2-nitrophenyl)sulfonyl)-8-((trityloxy)methyl)-1,4-diazabicyclo[4.2.0]octan-2-one 
• 1393923-62-0 6-allyl-7-(4-bromophenyl)-3-(2-nitrophenylsulfonyl)-3,6-diazabicyclo[3.1.1]heptane 
• 1393810-04-2 N-(((2R,3S,4S)-1-allyl-3-(4-bromophenyl)-4-(hydroxymethyl)azetidin-2-yl)methyl)-2-nitrobenzenesulfonamide 

Relevant academic research and scientific papers

SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF

Provided herein are compounds of Formulae (RL), (I), (II), (III), (IV), and (V), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, prodrugs, and isotopically labeled derivatives thereof. Also provided are pharmaceutical compositions, kits, and methods involving the inventive compounds for the treatment of metabolic disorders (e.g., diabetes, hyperglycemia, impaired glucose tolerance, insulin resistance, obesity). The compound are useful as substrate selective inhibitors of insulin-degrading enzyme (IDE).

Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries

The synthesis and diversification of a densely functionalized azetidine ring system to gain access to a wide variety of fused, bridged, and spirocyclic ring systems is described. The in vitro physicochemical and pharmacokinetic properties of representative library members are measured in order to evaluate the use of these scaffolds for the generation of lead-like molecules to be used in targeting the central nervous system. The solid-phase synthesis of a 1976-membered library of spirocyclic azetidines is also described.